Juno Therapeutics, Inc. (NASDAQ:JUNO)‘s stock had its “neutral” rating reaffirmed by equities researchers at Goldman Sachs Group, Inc. (The) in a research note issued to investors on Friday.

JUNO has been the topic of a number of other reports. Leerink Swann restated an “outperform” rating on shares of Juno Therapeutics in a research note on Monday, June 12th. Vetr upgraded Juno Therapeutics from a “strong sell” rating to a “sell” rating and set a $25.50 price target on the stock in a research note on Monday, August 14th. Zacks Investment Research downgraded Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 28th. Morgan Stanley raised their price target on Juno Therapeutics from $26.00 to $27.00 and gave the stock an “equal weight” rating in a research note on Monday, August 7th. Finally, Raymond James Financial, Inc. upgraded Juno Therapeutics from a “market perform” rating to an “outperform” rating and set a $45.00 price target on the stock in a research note on Tuesday, August 29th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the company’s stock. Juno Therapeutics currently has an average rating of “Hold” and a consensus price target of $35.95.

Shares of Juno Therapeutics (JUNO) traded down 2.187% during mid-day trading on Friday, hitting $43.742. The company’s stock had a trading volume of 614,931 shares. The stock’s 50 day moving average price is $40.17 and its 200 day moving average price is $29.25. Juno Therapeutics has a 52-week low of $17.52 and a 52-week high of $47.03. The company’s market cap is $4.59 billion.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.24). The firm had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The business’s quarterly revenue was down 22.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.64) earnings per share. Equities analysts forecast that Juno Therapeutics will post ($3.12) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Juno Therapeutics’ (JUNO) Neutral Rating Reaffirmed at Goldman Sachs Group, Inc. (The)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/06/juno-therapeutics-inc-juno-now-covered-by-goldman-sachs-group-inc-the.html.

In other Juno Therapeutics news, EVP Robert Azelby sold 12,850 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $44.95, for a total transaction of $577,607.50. Following the sale, the executive vice president now directly owns 37,439 shares of the company’s stock, valued at $1,682,883.05. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Sunil Agarwal sold 7,285 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $44.76, for a total value of $326,076.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,085,004 shares of company stock worth $219,551,561. Insiders own 15.26% of the company’s stock.

A number of large investors have recently bought and sold shares of JUNO. The Manufacturers Life Insurance Company raised its holdings in Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares during the period. Pacad Investment Ltd. bought a new stake in Juno Therapeutics during the second quarter valued at about $105,000. QS Investors LLC bought a new stake in Juno Therapeutics during the second quarter valued at about $135,000. Great West Life Assurance Co. Can raised its holdings in Juno Therapeutics by 80.5% during the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 3,800 shares during the period. Finally, Macquarie Group Ltd. bought a new stake in Juno Therapeutics during the second quarter valued at about $248,000. 67.38% of the stock is currently owned by institutional investors and hedge funds.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Stock Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related stocks with our FREE daily email newsletter.